https://doi.org/10.55788/82e9bac4
The cluster-randomised PACT-HF trial (NCT02112227) evaluated a transitional care service following HF hospitalisation [1,2]. Dr Tauben Averbuch (University of Calgary, Canada) and colleagues explored sex differences in clinical outcomes and annualised resource utilisation after HF hospitalisation in this population [2]. The study included 2,253 women and 2,188 men ≥18 years of age. Some notable differences at baseline were that women had a higher mean age (78.5 vs 73.9 years), more often resided in long-term care (18.9% vs 10.3%), had a higher left ventricular ejection fraction (49.0 vs 42.2), and had a higher prevalence of dementia (10.5% vs 7.1%); P<0.01 for all comparisons.
Among participants hospitalised for HF, 5-year clinical event rates were high. The primary outcome was all-cause mortality. Over half of all participants had died; 5-year all-cause mortality exceeded that of many cancers. No significant sex differences were observed in all-cause death (65.5% of women vs 63.6% of men), death in hospital (55.7% vs 56.7%, respectively), or re-admission (84.4% vs 85.4%, respectively).
Costs following HF hospitalisation were high; nearly half of these costs were driven by re-admission. Although mean annual costs per participant 1 and 5 years after hospitalisation did not differ significantly between men and women, the distribution of healthcare costs did vary. Costs of HF clinics and specialist billings were higher for men, whereas costs for home care and long-term care were higher for women. Healthcare utilisation in the 5 years after hospitalisation showed no differences between the sexes in terms of cardiac invasive care. However, women received fewer ambulatory visits (5.1 vs 6.7), more homecare visits (69.0 vs 54.2), and more cumulative days of long-term care (48.3 vs 21.9).
- Van Spall HGC, et al. JAMA. 2019;321:753–61.
- Averbuch T, et al. Sex-specific clinical outcomes and healthcare resource utilization for the 5 years following hospitalization for heart failure. Late breaking clinical trials: registries, Heart Failure 2024, 11–14 May, Lisbon, Portugal.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands Next Article
CD34+ stem cells promote reverse cardiac remodelling after acute MI »
« Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands Next Article
CD34+ stem cells promote reverse cardiac remodelling after acute MI »
Table of Contents: HFA 2024
Featured articles
Meet the Trialist: Innovating cardiac monitoring with MONITOR-HF
Trials: Pharmacology
Effects of semaglutide on MACE irrespective of HF status
SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM
ARIES-HM3 trial: Subgroup analysis in patients with prior need for aspirin
Three diuretic regimens compared in the DEA-HF study
Adding a mineralocorticoid receptor modulator in heart failure with CKD
SGLT2 Inhibitors
Empagliflozin did not reduce mortality for HF after MI regardless of T2D status
SGLT2 inhibitors decrease atrial fibrillation risk in patients with HFrEF
SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk
Trials: Other
Individualised diuretic titration in acute HF without a physician
Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF
CD34+ stem cells promote reverse cardiac remodelling after acute MI
Registries
Sex-specific outcomes and resource utilisation after HF hospitalisation
Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands
Devices
PAP-guided management system appears safe in patients with HF
Delivery of CRT guided by non-invasive anatomy assessment
RELIEVE-ing HFrEF with interatrial shunting
Miscellaneous
Algorithm-based remote patient monitoring was associated with lower mortality in a retrospective cohort study
High mortality and morbidity in suspected de novo HF in outpatient care
Bio-ADM as a marker for congestion in patients hospitalised for acute HF
Hypertonic saline not effective in ambulatory patients with heart failure?
No effect of low-dose carperitide on mortality or hospitalisation in acute HF
Related Articles
January 6, 2021
Could statins protect the heart from breast-cancer chemotherapy?
June 15, 2022
Surprise outcome for SODIUM-HF
October 26, 2021
Empagliflozin: First drug with clear benefit in HFpEF patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com